Jim Cramer Couldn't Stop Gushing About Johnson & Johnson (JNJ)'s Cancer Drugs [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm's shares are up by 46% year-to-date and have had a good December so far. During this time period, Johnson & Johnson (NYSE:JNJ) has reported several important developments. For instance, the firm announced on December 12th that it had secured the Food and Drug Administration's (FDA) approval for its New Drug Application for the AKEEGA drug to treat patients with certain kinds of prostate cancer. The AKEEGA update followed Johnson & Johnson (NYSE:JNJ)'s revelation on December 9th that the phase three study of TECVAYLI and DARZALEX FASPRO drugs had shown an 83% reduction in disease risk or death for patients suffering from with relapsed/refractory multiple myeloma (RRMM). Trong Nguyen / Shutterstock.com Johnson & Johnson (NYSE:JNJ)'s recent announcements have also been met with analyst enthusiasm as Bank of America raised its share price targe
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson Receives FDA Approval for TRUFILL n-BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma [Yahoo! Finance]Yahoo! Finance
- 3 Dividend Kings Delivering Generational Income & Market-Beating Returns [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson ?Value of Time????????2? ?????????????????? [CNET News]CNET News
- Unlock Health Appoints Jamie Mermelstein as Vice President of Digital Experience [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- JNJ's page on the SEC website